Similar articles

• Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.

  Brennan FM, Cope AP, Katsikis P, Gibbons DL, Maini RN, Feldmann M. Brennan FM, et al. Chem Immunol. 1995;60:48-60. Chem Immunol. 1995. PMID: 7857528 Review. No abstract available.
• Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.

  Feldmann M, Maini RN. Feldmann M, et al. Nat Med. 2003 Oct;9(10):1245-50. doi: 10.1038/nm939. Nat Med. 2003. PMID: 14520364 No abstract available.
• Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action.

  Feldmann M, Brennan F, Paleolog E, Taylor P, Maini RN. Feldmann M, et al. Eur Cytokine Netw. 1997 Sep;8(3):297-300. Eur Cytokine Netw. 1997. PMID: 9346366 Review. No abstract available.
• Tumor necrosis factor inhibitor therapy for rheumatoid arthritis.

  Naguwa SM. Naguwa SM. Ann N Y Acad Sci. 2005 Jun;1051:709-15. doi: 10.1196/annals.1361.115. Ann N Y Acad Sci. 2005. PMID: 16127011 Review.
• [Significance of tumor necrosis factor (TNF-alpha) in rheumatoid arthritis].

  Godyń-Swedzioł RM, Stańczyk J, Hilt J, Kowalski ML. Godyń-Swedzioł RM, et al. Przegl Lek. 2004;61(2):90-3. Przegl Lek. 2004. PMID: 15230148 Review. Polish.